Peripheral T-cell lymphoma · 4 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
TFC, then allo HSCT Variant #01 Partial | — | R 11 591 | — | — | — | ~1 | ~R 11 591 indirect | — |
BEAM Variant #01 Partial | — | R 4 346 | — | — | — | ~1 | ~R 4 346 indirect | — |
Cyclophosphamide and TBI Variant #01 | — | R 1 176 | — | — | ~90.0 mo | ~1 | ~R 1 176 PFS proxy · indirect | 2 |
Radiation therapy N/A - radiation | — | — | 49d | ~25.5 mo | ~10.6 mo | — | — | 24 |
4 of 4 regimens shown